BofA sees limited impact on Eli Lilly franchise from Novo’s GLP-1 price update
BofA says today’s announcement that Novo Nordisk (NVO) plans to reduce list prices for the LPG-1 is an eye-catching headline, but the update is unlikely to have any material impact on the US market in the company’s view. BofA views today’s action as an attempt to reduce copay/coinsurance costs for patients in settings where that…